Anlon Healthcare IPO Details
Anlon Healthcare is coming up with a book-built IPO of Rs. 121.03 crore, entirely through a fresh issue of 1.33 crore equity shares.
-
IPO Opens: 26 August 2025
-
IPO Closes: 29 August 2025
-
Basis of Allotment: 1 September 2025
-
Tentative Listing: 3 September 2025 on BSE & NSE
Price Band: Rs. 86 – Rs. 91 per share
Lot Size: 164 shares
-
Retail Minimum Investment: Rs. 14,104 (1 lot of 164 shares)
-
sNII Quota: 14 lots (2,296 shares) = Rs. 2,08,936
-
bNII Quota: 68 lots (11,152 shares) = Rs. 10,14,832
Book Running Lead Manager: Interactive Financial Services Ltd.
Registrar: Kfin Technologies Ltd.
Table of Contents
- GMP
- Reviews
- Subscription
- Allotment
Subscription Tally
| QIB | B HNI X | S HNI X | NII X | RII X | Total X |
| 1.07 | 7.56 | 16.69 | 10.61 | 47.26 | 7.12 |
| Applications: 334669 | |||||
| Subscription Review: Good subscription trend in RIIs |
|||||
Anlon Healthcare IPO Key Dates
| Anchor portion | |
| IPO opens on | 26 August 2025 |
| IPO Closes on | 29 August 2025 |
| IPO Allotment on | 1 September 2025 |
| Unblocking of Asba | 2 September 2025 |
| Credit of Shares | 2 September 2025 |
| Listing of Shares | 3 September 2025 |
Who are the promoters of Anlon Healthcare IPO?
Punitkumar R. rasadia, Meet Atulkumar Vachhani and Mamata punitkumar Rasadia are the promoters of the company.
The promoters hold 70.26% shares in the post IPO capital of the company.
What are the Objects of Anlon Healthcare IPO?
The Offer comprises a Fresh Issue by the Company and an Offer for Sale by the Selling Shareholders.
The net proceeds of the Offer are proposed to be utilised in the following manner:
Funding capital expenditure requirements for Proposed Expansion Rs.30.72 Crore
Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company Rs. 5 Crore.
Funding the working capital requirements of the Company Rs. 43.15 Crore
General Corporate Purposes
About Anlon Healthcare Limited
Incorporated in 2013, Anlon Healthcare Limited is engaged in the manufacturing of Pharma Intermediates and Active Pharmaceutical Ingredients (APIs).
The company specializes in high-purity pharmaceutical intermediates (used for API production) and APIs that are widely used in medicines, nutraceuticals, personal care, and veterinary health products. All products comply with leading pharmacopeia standards — IP, BP, EP, JP, and USP.
Key Offerings
-
Pharma Intermediates: Cyanoethylbenzoic acid, Ketonitrile, Methyldesloratadine (used as key starting/advanced intermediates in API manufacturing).
-
APIs: Used in formulations such as tablets, capsules, ointments, syrups, nutraceuticals, personal care and veterinary medicines.
-
Custom Manufacturing: Complex chemicals with higher purity and reduced impurities, tailored to customer requirements.
Approvals & Regulatory Strength
-
Drug Master File (DMF) Approvals: Received from ANVISA (Brazil), NMPA (China), and PMDA (Japan) for APIs like Loxoprofen Sodium Dihydrate and Loxoprofen Acid.
-
21 DMFs already filed with global authorities; applications in process for Ketoprofen and Dexketoprofen Trometamol.
Product Pipeline
-
65 commercialized products
-
28 products at pilot stage
-
49 products in laboratory testing
Infrastructure & Team
-
4 dedicated laboratories for testing and process improvements
-
34-member technical team, including 24 science graduates
-
105 employees + 8 contract workers (as of Jan 31, 2025)
